- Home
- RIGL vs CNNE Comparison
RIGL vs CNNE Comparison
Compare RIGL & CNNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | CNNE |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 609.0M |
| IPO Year | 2000 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RIGL | CNNE |
|---|---|---|
| Price | $39.16 | $14.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $45.67 | $20.25 |
| AVG Volume (30 Days) | 302.4K | ★ 407.5K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 4.47% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | $294,282,000.00 | ★ $499,700,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.75 | N/A |
| P/E Ratio | $30.67 | ★ N/A |
| Revenue Growth | ★ 64.15 | 3.37 |
| 52 Week Low | $24.84 | $10.46 |
| 52 Week High | $52.24 | $20.15 |
Technical Indicators
Market Signals| Indicator | RIGL | CNNE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.